Clinical trial
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With…
NCT00098085 · Agenus Inc., Industry · Completed
Key facts
| NCT number | NCT00098085 |
|---|---|
| Title | Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer |
| Official title | A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer |
| Lead sponsor | Agenus Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma, Lung Cancer, Pulmonary Cancer |
| Intervention type | Biological |
| Interventions | HSPPC-96 |
| Enrollment | 20 |
| Start date | Sep 1, 2003 |
| Primary completion | Nov 1, 2007 |
| First posted | Dec 6, 2004 |
| Last update posted | Mar 9, 2009 |
| Countries | United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: